Here is the design of a clinical trial:

Official Title: Mistletoe Therapy in Primary & Recurrent Inoperable Pancreatic Cancer. A Phase III Prospective Randomized Double Blinded Multicenter Parallel Group Placebo Controlled Clinical Trial on Overall Survival and Quality of Life

Included conditions:
- Pancreatic Cancer

Study Armgroups:
- {'label': 'Mistletoe extract (Iscador Qu)', 'type': 'EXPERIMENTAL', 'description': 'Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg', 'interventionNames': ['Drug: Mistletoe extract (Iscador Qu)']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'isotonic saline solution, subcutaneous use 3 injections/week', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Mistletoe extract (Iscador Qu)', 'description': '1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg', 'armGroupLabels': ['Mistletoe extract (Iscador Qu)'], 'otherNames': ['Fermented aqueous extract of Viscum album ssp album (L.)']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': '1ml subcutaneous injection 3 times/week', 'armGroupLabels': ['Placebo'], 'otherNames': ['Isotonic saline solution']}

Primary Outcomes:
- {'measure': 'Overall survival (OS)', 'description': 'OS defined as time from randomization to death for any reason', 'timeFrame': 'End of study (estimated 3 years)'}

Please estimate the sample size based on the assumption: 
A two-sided log rank test with a 5% significance level and 90% power was used. The study also considered a higher proportion of participants in the palliative chemotherapy strata and longer time from diagnosis to trial inclusion.
Sample size {14}
        Calculation of sample size was based on a number of considerations based on comparability with the randomised controlled trial on ME in advanced pancreatic cancer conducted in Serbia [36]. A basic assumption was that OS data from the control group in Serbia were comparable to OS data from Swedish patients not eligible for palliative chemotherapy. This assumption was supported by available quality assessments on survival in this type of patients undergoing palliative supportive care in Stockholm (unpublished data). Moreover, HR was estimated to be affected by longer OS for patients eligible for palliative chemotherapy due to better prognosis in general, expected higher proportion of participants in strata for palliative chemotherapy than in strata for best supportive care, potentially longer OS in control groups in both strata due to extensive palliative care [56] and expected longer time from diagnosis to trial inclusion than in Serbia. Finally, pragmatic reasons affecting feasibility (academic trial, comparatively rare type of cancer, trial duration) were considered.
        A two-sided log rank test with an overall sample size of 290 patients (145 in the placebo group and 145 in the ME group) achieves 90% power at a 5% significance level to detect a hazard ratio of 0.67. In the placebo group, survival time in patients not eligible for palliative chemotherapy is expected to be shorter than for patients receiving palliative chemotherapy. However, the effect size for patients receiving ME compared to patients in the placebo group with respect to overall survival is expected to be the same in the two strata, i.e. a hazard ratio of 0.67.
        Ancillary studies
Within the biomarker study, blood samples from at least 60 patients will be collectedWithin the qualitative study, approximately 30 participants from both the intervention and placebo groups will be interviewed